ArticleMed (New York, N.Y.)2023
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Registry-linked trialAbstract readLetter
In one paragraph
Article in Med (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04885452 (Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU), which is not on this map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Who cites it
14 citing papers in PubMed.
- Article
- Is early combination therapy associated with lower risk of respiratory failure in severely immunocompromised hosts with COVID-19? a target trial emulation study from the omicron-dominant era.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Temperature-dependent replication and sensitivity to innate immunity of human coronavirus HKU1.Nature communications · 2026Article
- Recurrent Cytopathic Effects and Prolonged Viral Shedding in an Immunocompromised Patient With Malignant Lymphoma Treated With Rituximab and Bendamustine: A Case of Coronavirus Disease 2019 Relapse.Clinical case reports · 2026Article
- Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort study.iScience · 2025Article
- Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo.Nature communications · 2025Article
- Article
- Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.Viruses · 2024Article
- Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.iScience · 2024Article
- Akaluc bioluminescence offers superior sensitivity to trackiScience · 2024Article
- Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.Nature communications · 2024Article
- Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.bioRxiv : the preprint server for biology · 2024Article
- Article
- Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Timothée BruelVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France. Electronic address: timothee.bruel@pasteur.fr.
Lou-Léna VrignaudVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Sorbonne Université, Paris, France.
Françoise PorrotVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
Isabelle StaropoliVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
Delphine PlanasVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France.
Florence Guivel-BenhassineVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
Julien PuechLaboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
Matthieu ProtG5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
Sandie MunierG5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
William Henry BollandVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; École Doctorale BioSPC 562, Université de Paris, Paris, France.
Cathia SouliéSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Virology Department, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
Karen ZafilazaSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Virology Department, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
Clovis Lusivika-NzingaSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France.
Marie-Laure MeledgeSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France.
Céline DorivalSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France.
Diana MolinoINSERM-ANRS Maladies Infectieuses Emergentes, 75015 Paris, France.
Hélène PéréLaboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France; Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France.
Youri YordanovSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Hôpital Saint-Antoine, Service d'Accueil des Urgences, Assistance Publique - Hôpitaux de Paris, AP-HP, Sorbonne Université, Paris, France.
Etienne Simon-LorièreG5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France; Institut Pasteur, Université Paris Cité, National Reference Center for viruses of respiratory infections, Paris, France.
David VeyerLaboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France; Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France.
Fabrice CarratSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Hôpital Saint-Antoine, santé publique, APHP Paris, Paris, France.
Olivier SchwartzVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France.
Anne-Geneviève MarcelinSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Virology Department, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
Guillaume Martin-BlondelService des Maladies Infectieuses et Tropicales, CHU de Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM, Université Toulouse III., Toulouse, France. Electronic address: martin-blondel.g@chu-toulouse.fr.
ANRS 0003S CoCoPrev Study GroupINSERM-ANRS Maladies Infectieuses Emergentes, 75015 Paris, France.
Funding
Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central AfricaU01AI151758 · NIAID · INSTITUT PASTEUR · PI SAKUNTABHAI, ANAVAJ, SIMON-LORIERE, ETIENNE · 2020 to 2024
$6.7MNIAID NIH HHS U01 AI151758
Abstract
Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.
Indexed as
Antibodies, Monoclonal, HumanizedImmunocompromised HostAntibodies, NeutralizingAntiviral AgentsHumansProspective StudiesAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral Agentssotrovimab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04885452ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.